Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


Gene therapy play Orchard raises 30.7 million

Orchard Therapeutics (London, U.K.) raised $30.7 million in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies …

POPULAR TAGS

23,5 million euro for a cutting-edge allergy treatment

Written by IL on in the category news with the tags , .


ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announced the results of its IPO of new shares. The company raised € 23.5 million in new capital at a final offer price of € 7.00 per share and initial market capitalization of € 89.3 million. This allows ASIT to further develop their current product pipeline, to cover general corporate purposes and to accelerate the discovery of product candidates for the new ASIT+™ platform.

The exciting new ASIT+TM technology platform relies on the administration of only 4 sequential immunizations of patients who suffer from hay fever, guaranteeing protection during an entire year. Currently, the 25 million people in Europe who experience hay fever and who need to protect themselves during the pollen season (mid May-late August) must take daily anti-allergenic pills or injections. ASIT Biotech innovation therapy is meant to result in a short treatment, expected to improve patient compliance and daily-life effectiveness.

Read more about: , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


Gene therapy play Orchard raises 30.7 million

Orchard Therapeutics (London, U.K.) raised $30.7 million in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven GSK Turnstone UGent Itera Life Science Janssen V-Bio Ventures Biowin Flanders.bio XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.